# Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

> **NCT03914300** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Differentiated Thyroid Gland Carcinoma
- Follicular Variant Thyroid Gland Papillary Carcinoma
- Poorly Differentiated Thyroid Gland Carcinoma
- Refractory Differentiated Thyroid Gland Carcinoma
- Refractory Thyroid Gland Carcinoma
- Tall Cell Variant Thyroid Gland Papillary Carcinoma
- Thyroid Gland Follicular Carcinoma
- Thyroid Gland Oncocytic Carcinoma
- Thyroid Gland Papillary Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib S-malate
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03914300
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-10
- **Primary completion:** 2024-10-17
- **Final completion:** 2026-12-17
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03914300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03914300, "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03914300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*